-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target

Benzinga·11/04/2026 09:59:58
语音播报
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.